NEW YORK (GenomeWeb) – OncoDNA said today that a number of private health insurers, including BUPA Global Insurance, will now reimburse for its OncoStrat&Go testing in the United Kingdom.

OncoStrat&Go is a combined liquid biopsy and tissue test intended to provide a complete genetic profile of a patient's tumor to predict response to targeted, immunotherapeutic, and chemotherapy treatments.

BUPA Global has created a specific code for the reimbursement of the test, while other UK insurers will use a generic code, OncoDNA said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.